Aridis Pharmaceuticals Stock (NASDAQ:ARDS)
Previous Close
$NaN
52W Range
- - $0.09
50D Avg
-
200D Avg
$0.04
Market Cap
$4.46K
Avg Vol (3M)
$5.64K
Beta
-26.04
Div Yield
-
ARDS Company Profile
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
ARDS Performance
Peer Comparison
Ticker | Company |
---|---|
ZVSA | ZyVersa Therapeutics, Inc. |
HOTH | Hoth Therapeutics, Inc. |
RVPH | Reviva Pharmaceuticals Holdings, Inc. |
ABVC | ABVC BioPharma, Inc. |
ADTX | Aditxt, Inc. |
REVB | Revelation Biosciences, Inc. |
RNAZ | TransCode Therapeutics, Inc. |
AKTX | Akari Therapeutics, Plc |
SGTX | Sigilon Therapeutics, Inc. |
DRMA | Dermata Therapeutics, Inc. |
VRAX | Virax Biolabs Group Limited |
KOD | Kodiak Sciences Inc. |
EYEN | Eyenovia, Inc. |
NRBO | NeuroBo Pharmaceuticals, Inc. |
UNCY | Unicycive Therapeutics, Inc. |
ACST | Acasti Pharma Inc. |
CGTX | Cognition Therapeutics, Inc. |
ATXI | Avenue Therapeutics, Inc. |